Head dOwn Position Before Endovascular Treatment for Large veSsel Occlusion (HOPES5): a Prospective, Randomized, Open Label, Blinded-end Point, Multi-center Study

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Recent studies suggest that head-down positioning (HDP) intervention may improve outcomes in ischemic stroke. In the era of reperfusion therapy, a key protective strategy is to administer neuroprotective interventions before recanalization to reduce the loss of the ischemic penumbra, thereby salvaging more penumbral tissue after revascularization and ultimately improving clinical outcomes. Based on this concept, and considering the neuroprotective effects of HDP, the investigators hypothesize that HDP intervention prior to endovascular therapy (EVT) in patients with large vessel occlusion could improve clinical outcomes. This hypothesis is further supported by a recent clinical study (NCT03728738), which demonstrated that compared to a sitting up position (30°), a flat supine position (0°) before EVT significantly reduced the incidence of neurological deterioration prior to the procedure. Building on the above rationale, this trial aims to investigate the efficacy and safety of HDP intervention prior to EVT in patients with large vessel occlusion.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years;

• Patients with acute large vessel occlusion scheduled for endovascular thrombectomy within 24 hours of symptom onset;

• Baseline National Institute of Health Stroke Scale (NIHSS) ≥ 6;

• Expected waiting time from randomization to femoral artery puncture is more than 30 minutes;

• ASPECTS/pc-ASPECTS score ≥ 6 on baseline non-contrast CT or DWI;

• Modified Rankin Scale score before stroke onset ≤ 1;

• Signed informed consent by patient or their legally authorized representative.

Locations
Other Locations
China
Hui-Sheng Chen
RECRUITING
Shenyang
Time Frame
Start Date: 2025-09-02
Estimated Completion Date: 2026-09-30
Participants
Target number of participants: 210
Treatments
Experimental: HDP
the HDP group receive -20° Trendelenburg prior endovascular treatment.
No_intervention: Control
Related Therapeutic Areas
Sponsors
Leads: General Hospital of Shenyang Military Region

This content was sourced from clinicaltrials.gov